

ALS mutations in FUS causes neuronal dysfunction and death in *C. elegans* by a dominant gain-of-function mechanism

Tetsuro Murakami¹, Seung-Pil Yang¹, Lin Xie², Taizo Kawano², Donald Fu¹, Asuka Mukai¹, Christopher Bohm¹, Fusheng Chen¹, Janice Robertson¹, Hiroshi Suzuki¹, Gian Gaetano Tartaglia³, Michele Vendruscolo³, Gabriele S. Kaminski Schierle⁴, Fiona T.S. Chan⁴, Aileen Moloney⁵, Damian Crowther^{5,6}, Clemens F. Kaminski⁴, Mei Zhen², Peter St George-Hyslop^{1,6}

1. Tanz Centre for Research in Neurodegenerative Diseases, and Depts of Medicine, Laboratory Medicine and Pathobiology, and Physiology, University of Toronto, Toronto, Ontario, Canada, M5S 3H2.
2. Samuel Lunenfeld Research Institute, Mount Sinai Hospital, and Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada, M5G 1X5.
3. Department of Chemistry, University of Cambridge, Cambridge, UK.
4. Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK
5. Department of Genetics, University of Cambridge, Cambridge, UK
6. Cambridge Institute for Medical Research, and Dept of Clinical Neurosciences, University of Cambridge, Cambridge, UK, CB2 0XY.

Correspondence should be addressed to: P. St George-Hyslop p.hyslop@utoronto.ca or phs22@cam.ac.uk

Competing Financial Interests: None

© The Author 2011. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

It is unclear whether mutations in FUS cause familial ALS via a loss-of-function effect due to titrating FUS from the nucleus, or a gain-of-function effect from cytoplasmic over-abundance. To investigate this question we generated a series of independent *C. elegans* lines expressing mutant or wild-type human FUS. We show that mutant FUS, but not wild-type FUS, causes cytoplasmic mislocalisation associated with progressive motor dysfunction and reduced lifespan. The severity of the mutant phenotype in *C. elegans* was directly correlated with the severity of the illness caused by the same mutation in humans, arguing that this model closely replicates key features of the human illness. Importantly, the mutant phenotype could not be rescued by overexpression of wild-type FUS even though wild-type FUS had physiological intracellular localisation, and was not recruited to the cytoplasmic mutant FUS aggregates. Our data suggest that FUS mutants cause neuronal dysfunction by a dominant gain-of-function effect related either to neurotoxic aggregates of mutant FUS in the cytoplasm or to dysfunction in its RNA binding functions.

INTRODUCTION

Mutations in the fused in sarcoma (FUS; ALS6) genes (1-3) cause familial forms of Amyotrophic Lateral Sclerosis (ALS), and FUS may contribute to sporadic cases of frontotemporal lobar degeneration (FTLD). FUS encodes an RNA-binding protein that, under physiological conditions, is almost exclusively expressed in the nucleus (4-6). However, in patients with pathogenic FUS mutations and in patients with sporadic forms of FTLD-FUS, the FUS protein accumulates in the cytoplasm of neurons in the spinal cord and brain (7-10). The majority of mutations occur in the C-terminus of FUS protein, which is thought to contain a nuclear targeting signal (11). This has led to the conclusion that mislocalisation of mutant FUS causes either a loss-of-function effect (because of titration of FUS from the nucleus), or a gain-of-function effect (arising from aberrant accumulation of FUS in the cytoplasm)(12, 13). The fact that mutations in the Tar DNA Binding Protein 43 (TDP-43), another RNA binding protein, also cause familial ALS, has led to the hypothesis that FUS and TDP-43 might work by the same mechanism (13). To further explore the mechanism by which mutant FUS protein causes ALS, we chose to create transgenic models bearing wild type or mutant human FUS in *C. elegans*. We chose this model for three reasons. First, *C. elegans* has an orthologue of human FUS, encouraging the notion that models built in this animal would have biological validity. Second, the genetics of *C. elegans* provides a powerful tool to seek upstream and downstream partners via enhancer and suppressor screens. Third, the optical transparency of *C. elegans* allows the application of biophysical techniques to monitor the distribution and folding state of proteins of interest (14).

RESULTS

A series of wild-type and mutant human FUS transgenes were generated and were then expressed in *C. elegans* under the control of a pan-neuronal promoter (Figure 1). These transgenes included: 1) full-length wild-type human FUS (WT-FUS); 2) four different missense mutations associated with varying clinical severity (as defined by age-at-onset and by disease duration) of human ALS (R514G, R521G = mild; R522G = moderate; and P525L = severe) (1-3) (Supplementary Table 1); and 3) two different C-terminal truncated FUS constructs (FUS513 and FUS501 - lacking the C-terminal 13 and 25 amino acids of FUS respectively). While the C-terminal truncated constructs are artificial, they are very similar to several human C-terminal splicing/frame-shifting truncation mutations that are also associated with severe ALS phenotypes (15, 16). Each construct was cloned into a vector containing a *C. elegans* pan-neuronal promoter *Prgef-1* and an in-frame green fluorescent protein (GFP S65T) or red fluorescent protein (TagRFP) at the N-terminus. Multiple stable integrated transgenic FUS lines were obtained for each mutant and wild type FUS construct. The levels of FUS mRNA were determined for each line by qRT-PCR, and transgenic lines with similar levels of expression (1.00 - 1.78 fold of WT-FUS) were chosen for subsequent experiments (Supplementary Figure 1).

Mutations in FUS cause its accumulation in cytoplasmic inclusions

Transgenic animals expressing only GFP under the control of the same pan-neuronal *Prgef-1* promoter showed diffuse nuclear and cytoplasmic signals in neurons (data not shown). In contrast, the GFP-tagged full-length WT-FUS was detected only in the nuclei of neurons (nuclear FUS/total FUS ratio = $93 \pm 3\%$, n = 20 animals/transgenic strain) (Figures 2A,B and 3A). The nuclear localisation of WT-FUS is consistent with the physiological subcellular

localization of FUS in healthy human neurons (1, 2). Immunostaining with anti-FUS antibody revealed that the FUS immuno-reactivity fully replicated the subcellular distribution of the GFP signal in the same animals, indicating that the GFP tag was a reliable indicator of FUS localization *in vivo* (Supplementary Figure 2).

In animals expressing R514G and R521G mutations, which have a mild ALS phenotype in human ALS cases (1), the pattern of GFP-FUS was identical to WT-FUS at all ages (nuclear FUS/total FUS ratio = $92 \pm 3\%$ and $96 \pm 3\%$ respectively, Figures 2A,B and 3A). In animals expressing the R522G mutation, which has a moderate human ALS phenotype (1), FUS was also present in nuclei of neurons, but there was some FUS diffusely present in the cytoplasm (nuclear FUS/total FUS ratio = $59 \pm 10\%$, $p < 0.001$ compared to WT-FUS, Figures 2A,B and 3A). In animals expressing the clinically severe P525L mutation, nearly half of the total neuronal FUS was located in the cytoplasm in an uneven, clumpy distribution (nuclear FUS/total FUS ratio = $52 \pm 9\%$, $p < 0.001$ compared to WT-FUS, Figures 2A,B and 3A). Both truncated FUS constructs also showed strong, clumpy, cytoplasmic FUS with less nuclear FUS (nuclear FUS/total FUS ratio = $44 \pm 4\%$ and $43 \pm 5\%$ for FUS513 and FUS501 respectively, Figure 2A,B and 3A).

Mutant FUS accumulates and aggregates in neuronal cytoplasm *in vivo*

To determine whether the cytoplasmic inclusions contained insoluble aggregates of FUS, we undertook sequential extraction of animals with RIPA and then urea buffer. This analysis revealed that there were increased steady state levels of FUS in animals that had cytoplasmic FUS accumulation (Figure 3B), and that some of this accumulated protein was in the form of SDS-insoluble, urea soluble aggregates (Figure 3C). All animals had similar levels

of transgene mRNA expression, and there was no correlation between the level of transgene expression and the abundance of FUS (Supplementary Figure 1). The differences in steady-state levels of FUS protein therefore likely reflect differences in the amount of cytoplasmic aggregated FUS, which in turn could reflect differences in the intrinsic aggregation propensity of the various mutant FUS proteins.

Animals with FUS aggregates show progressive motor defects and die prematurely

To determine whether the cytoplasmic aggregation of FUS was accompanied by functional deficits, we assessed the motor activity of the transgenic animals by employing a standard thrashing assay (http://www.wormbook.org/chapters/www_behavior/behavior.html#sec7). This assay measured motor activity by counting the frequency of body bends when animals were placed in liquid M9 buffer. At three days of age (i.e. young adults) animals expressing only a GFP transgene had a slight motor disturbance ($100.7 \pm 5.6/\text{min}$) compared to non-transgenic N2 animals of the same age ($n = 20$, $115.7 \pm 6.3/\text{min}$, $p < 0.05$, Figure 3D). Animals expressing WT-FUS had a similar minor impairment of motor function ($104.8 \pm 5.0/\text{min}$), indicating that expression of WT-FUS *per se* has little or no toxicity. The motor function of animals expressing the clinically-mild R514G and R521G mutations, and which had predominantly nuclear FUS, was indistinguishable from WT-FUS and GFP-only animals (R514G $103.5 \pm 6.0/\text{min}$; R521G = $103.8 \pm 5.9/\text{min}$). In contrast, animals expressing either the moderate R522G ($96.3 \pm 4.9/\text{min}$) or the severe P525L mutations ($91.8 \pm 5.2/\text{min}$) showed significantly impaired motor function compared to WT-FUS ($p < 0.05$ and $p < 0.001$ respectively). Animals expressing C-terminal truncated FUS513 ($69.7 \pm 8.9/\text{min}$) or FUS501 ($54.6 \pm 8.7/\text{min}$) also had significantly impaired motor function compared to

WT-FUS ($p < 0.001$). Representative locomotor behaviors of the animals are shown in Supplementary Data (Movies SM1-SM5).

Because human FUS mutations differ both in their age-of-onset and rates-of-progression, we next assessed rates of progression by comparing motor performance of three-day-old and six-day-old adult animals ($n = 20$ for each strain). The six-day old non-transgenic wild type (N2), WT-FUS, R514G and R521G animals showed minor degrees of age-related decline compared to the three-day old N2 animals ($-11.0 \pm 0.8\%$, $-9.2 \pm 1.3\%$, $-10.8 \pm 1.7\%$ and $-7.5 \pm 1.4\%$, respectively; $p = \text{N.S.}$) (Figure 3E, F). However, the decline in R522G, P525L, FUS513 and FUS501 animals ($-19.1 \pm 1.6\%$, $-25.3 \pm 1.3\%$, $-27.7 \pm 1.8\%$ and $-22.3 \pm 2.1\%$, respectively) was significantly greater than in N2 and WT-FUS animals ($p < 0.001$). These differences in rates of progression in mutant FUS animals closely parallel the differences in rates of progression of ALS in humans with the same FUS mutations.

As is the case with human ALS, this progressive motor paralysis was also accompanied by accelerated mortality. At three days of adult age, all transgenic animals appeared morphologically similar to non-transgenic N2 animals, and were not distinguishable in size (Figure 4A). However, at about six days of age, P525L, FUS513, and FUS501 animals became smaller compared to WT-FUS animals of the same age. By eight days of age, most of the P525L, FUS513, and FUS501 animals were partially or completely paralysed, severely shrunken, and many were dead (Figure 4A). Kaplan-Meier analyses ($n = 20$ animals/transgenic strain) revealed that under our culture conditions, the mean life spans of animals expressing WT-FUS or the mild ALS mutations (R514G and R521G) were not different from N2 animals (Figure 4B and C). In

contrast, the mean life spans of animals expressing the R522G, P525L, FUS513 and FUS501 mutants were reduced to 9.7 ± 0.4 days, 9.3 ± 0.3 days, 8.9 ± 0.3 days and 8.1 ± 0.2 days, respectively, and were significantly shorter than non-transgenic N2 (12.8 ± 0.3 days; $p < 0.001$) and WT-FUS animals (12.1 ± 0.4 days; $p < 0.001$). Neurons from six-eight day old R522G, P525L, FUS513 and FUS501 animals also had abundant FUS-positive granules in the cytoplasm that were not present at younger ages (Figure 4D).

Cellular stress exacerbates both cytoplasmic mislocalization of FUS and motor dysfunction

Because heat stress has been previously shown to cause mislocalization of FUS, we applied brief periods of thermal stress (35°C for 30 minutes), and then monitored both the subcellular distribution of FUS and the severity of motor dysfunction. Because FUS is an RNA binding protein, we were particularly interested to determine if it might colocalize with cytoplasmic stress granules, which can be monitored by Poly (A) binding protein (PAB-1)(17). At all ages, animals over-expressing PAB-1 tagged at the N-terminus with mCherry showed only diffuse cytoplasmic fluorescent signals with no apparent stress granules under normal conditions (Figure 5A, no HS). However, 30 minutes after application of 35°C heat shock, PAB-1 coalesced into numerous cytoplasmic granules (Figure 5A). These PAB-1 positive stress granules slowly disappeared, and PAB-1 staining reverted to the basal diffuse cytoplasmic distribution by 6 hours after heat shock (Figure 5A).

When PAB-1 was co-expressed with either WT-FUS or with mutant FUS, a small amount of PAB-1 positive stress granules were observed under basal conditions (Fig 5B). In the double transgenic animals expressing wild-type or mutant FUS and PAB-1, under the same basal

conditions, the distribution and morphology of FUS was identical to that in single transgenic FUS animals, indicating that PAB-1 does not affect localization of either WT-FUS or mutant FUS animals *per se*. Following the heat shock, WT-FUS animals exhibited a small increment in the number of stress granules in the cytoplasm but there was no corresponding cytoplasmic accumulation of FUS (Fig 5B). In strong contrast, when the same heat shock stimulus was applied to the R522G, P525L or FUS501 animals, all three mutant FUS lines showed more stress granules and obvious recruitment of the mutant FUS to the heat-stress-induced granules.

Concomitantly, we assessed motor function in these transgenic animals. All animals showed impaired motility immediately after the heat shock. However, animals expressing WT-FUS, and animals expressing the very mild ALS mutants (R514G and R521G) all rapidly recovered to baseline motor function within 30 minutes. In sharp contrast, all of the transgenic animals expressing the moderate and severe ALS mutants that cause cytoplasmic aggregates of FUS showed persistent motor deficits at 30 minutes after the heat shock (Figure 5C, $p < 0.001$, compared to WT-FUS animals). Other assays of neuronal activity, such as escaping behaviour following body-touch, also showed a persistent post-heat-shock motor defect in the animals with persistent cytoplasmic FUS (Supplementary Figure 3). These results support the notion that cytoplasmic accumulation of FUS is neurotoxic, but does not exclude the possibility that mutant FUS binds wild-type FUS and titrates it from the nucleus.

Wild-type FUS does not rescue mutant FUS and is not recruited to mutant FUS aggregates

To test the hypothesis that mutant FUS might remove WT-FUS from the nucleus, and thereby cause a loss-of-function effect, we generated transgenic animals expressing wild-type FUS labelled with TagRFP (TagRFP-WT-FUS) under the same pan-neuronal promoter. TagRFP-WT-FUS, like the previously described GFP-WT-FUS, was expressed in the nucleus, but was not recruited onto stress granules following heat shock and was not associated with significant neurological deficits (Figure 6A and B, n = 10 each). In sharp contrast, the double transgenic animals (TagRFP-WT-FUS; GFP-FUS-P525L) showed the presence of TagRFP-WT-FUS in the nucleus and GFP-FUS-P525L in the nucleus and cytoplasm under basal conditions (Figure 6A). Following heat shock, significant quantities of GFP-FUS-P525L were recruited to stress granules, but the TagRFP-WT-FUS remained in the nucleus (Figure 6A). Importantly, these double transgenic animals and the single transgenic GFP-FUS-P525L animals had equivalent degrees of impaired motor activity, and equivalent degrees of sensitivity to heat stress (Figure 6B). Mutant FUS is therefore likely to cause ALS through a dominant gain-of-function effect, instead of a loss-of-function effect through titrating and reducing the wild-type FUS function.

DISCUSSION

The experiments reported here demonstrate that pathogenic missense mutations in FUS that cause ALS in humans, also cause neuronal dysfunction and death of *C. elegans* expressing these same mutant proteins. Importantly, there are strong parallels in the genotype-to-phenotype correlations between the human disease and the phenotypes in *C. elegans* described here. These

similarities strongly argue that the mutant human proteins, when expressed in *C. elegans*, are closely modeling a fundamental property of these mutations in humans.

Our data indicate that ALS-associated mutations in FUS likely cause neurodegeneration via a toxic gain-of-function effect that is likely to be a consequence of the accumulation of FUS in the cytoplasm, rather than titration of FUS from its physiological location in the nucleus. This toxic gain-of-function effect could be mediated by either of two mechanisms. First, as is widely held in the field, it is conceivable that this toxic effect could be attributable to changes in RNA metabolism induced by the mutant FUS. Second, it is also possible that the aggregated FUS itself is the neurotoxic moiety, as is the case for several other neurotoxic intracellular and extracellular protein aggregates (e.g. tau, alpha-synuclein and huntingtin). Under such circumstances, the mutant, aggregation-prone forms may have a novel function unrelated or only partly related to the native function. Such is the case with ALS-inducing mutations in SOD1, which do not appear to work via alterations in superoxide dismutase activity (18). The animal models described here will be of use in the necessary work that will be required to discriminate these two possibilities. Additional work will also be required to understand the functional significance of binding of mutant FUS to stress granules, which have a role in cell viability and recovery after stress (11, 19, 20). A similar situation exists for.

MATERIALS AND METHODS

Transgenic FUS worms

Animals were maintained on NGM plates (1.8% agar, 0.3% NaCl, 0.25 % peptone, 25 mM KPO₄, 1 mM MgSO₄, 1 mM CaCl₂ and 5 µg/ml cholesterol) at 22°C. Full length (FL)

human FUS/TLS cDNA (NM_004960) (WT-FUS) was mutated to contain either one of five clinical mutations (R514G, R521G R522G, R524S and P525L). Two C-terminal truncated FUS constructs were generated (FUS513 and FUS501) lacking the C-terminal 13 and 25 amino acids of FUS respectively. Each construct was injected together with *lin-15* rescuing plasmid into a temperature sensitive *lin-15* (*n765*) allele, and *lin-15* (+) positive animals were selected for further analysis(21). These transgenes were integrated into the genome to generate stable transgenic lines by UV irradiation, and the lines were outcrossed >6 times with N2 wild type strain. Constructs used in this study are summarized in Figure 1.

Poly (A) binding protein (PAB-1) was used as a marker for stress granules(17). PAB-1 was cloned into the pJH897 vector with the tag replaced with mCherry at N-terminus, and was injected, solely or together with FUS constructs, along with the *lin-15* rescuing plasmid into *lin-15* worms. The N2 strain, and transgenic animals expressing only GFP (GFP-only) animals were used as negative controls.

Quantitative RT-PCR

Transgene expression in each integrated strain was determined using quantitative real-time PCR. Total RNA was prepared from L4 stage animals with TRIzol reagent (Invitrogen) and RNeasy kit (Qiagen, USA) according to the manufacturer's instructions. cDNA was synthesized with AffinityScript reverse transcriptase (Stratagene, USA) and was amplified with primers: forward, 5'-TAAATTTGGTGGCCCTCGGG-3'; and reverse, 5'-TCACCCAGGCCTTGCACAAA-3'. The amplification was monitored using SYBR Green

Premix Ex Taq reagent (Takara Bio, Japan) in ABI PRISM 7500 Real-Time PCR System (Applied Biosystems, USA) with *gpd-2* as an internal control.

Immunohistochemistry

FUS localization in neurons was assessed by fixation of the animals with 4% paraformaldehyde in MRWB buffer (80 mM KCl, 20 mM NaCl, 10 mM EGTA, 5 mM spermidine HCl, 15 mM Na PIPES and 25% methanol, pH 7.4); reduction with 1% 2-mercaptoethanol in BO_3 buffer (25 mM H_2BO_3 and 125 mM NaOH), then oxidation in 0.3% $\text{H}_2\text{O}_2/\text{BO}_3$ buffer and incubation with primary antibody (monoclonal anti-GFP antibody (Invitrogen, 1:200 dilution) or rabbit polyclonal anti-FUS antibody (Abcam 1:200 dilution) overnight at room temperature. After several washes, the animals were incubated with secondary antibody (1:400 dilution), washed again, and then mounted in DAPI to stain nuclei (Molecular Probes, USA).

Nuclear FUS quantification

To quantify the ratio of nuclear to cytoplasmic FUS, fluorescent microscopic images of neurons in the body were used so that signals from other nearby neurons were not counted. Using Image J, the nucleus and cytoplasm of the neuron was cropped and the pixels were counted (3 day-old animals, $n = 20$ animals, 10 neurons from each). Pixels that overlapped with DAPI were considered to be nuclear, and pixels that did not were considered cytoplasmic.

Thrashing assay

Animals from each transgenic line were picked at L4 stage (n = 20). Sixteen hours later, the 3-day-old young adult animals were transferred into 5 microlitres of M9 buffer (0.6% Na₂PO₄, 0.3% KH₂PO₄, 0.5% NaCl, 0.01% NH₄Cl) on a glass slide. Thirty seconds after the transfer, the frequency of the body bending was counted for one minute(22). The same protocol was used to assess motor function in 6-day-old adults.

Heat shock treatment

Animals were picked at L4 stage (n = 16) and kept at 22°C. Sixteen hours later, the animals were subjected to heat shock by incubation at 35°C for 30 minutes. After heat shock, the animals were returned to the 22°C-incubator for recovery, and were then assessed for functional deficits at 30 minutes after heat shock.

Fluorescence microscopy

Transgenic FUS animals with or without heat shock were anesthetized in 20 mM sodium azide in M9 buffer, mounted on an agarose pad with cover slip, and examined with standard fluorescent microscopes or confocal microscope (Nikon H600L, Japan).

Lifespan analysis

Animals were placed onto NGM plates (n = 20), replated daily and the number of live animals were counted. Immobile, shrunken animals were considered to have died.

Western blot analysis

Animals were lysed in RIPA buffer with sonication. After removing undissolved debris by centrifugation, protein concentrations of the lysates were determined by BCA assay. Equal amounts of protein were subjected to NuPAGE Bis-Tris (Invitrogen); transferred onto nitrocellulose membrane (Whatman, Germany); and detected by Western blotting with anti-GFP (Abcam, USA), anti-FUS (Santa Cruz Biotechnology, USA) or anti-tubulin (Abcam) antibodies. For analysis of the solubility of FUS proteins, RIPA lysates were centrifuged at 100,000 *g* for 30 min at 4 °C. The pellets were resuspended in urea buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris-HCl, pH 8.5), sonicated, and centrifuged at 100,000 *g* for 30 min at room temperature (10).

Statistical analysis

For statistical analysis, the unpaired Student's *t*-tests, and ANOVA were performed with SigmaPlot version 11.0.

CONFLICTS OF INTEREST

The authors have no conflicts of interest.

ACKNOWLEDGEMENTS

We thank Drs. Seydoux (Johns Hopkins University) and Schisa (Central Michigan University, USA) for PAB-1 construct.

FUNDING

This work was supported by grants from the Wellcome Trust, Canadian Institutes of Health Research, the Medical Research Council, the Biotechnology and Biological Sciences Research Council, the Howard Hughes Medical Institute, Safra Foundation, Canada Research Chairs, and the Alzheimer Society of Ontario. SPY received a post-doctoral fellowship from the Korean National Research Foundation.

REFERENCES

- 1 T.J. Kwiatkowski, Jr., D.A. Bosco, A.L. Leclerc, E. Tamrazian, C.R. Vanderburg, C. Russ, A. Davis, J. Gilchrist, E.J. Kasarskis, T. Munsat, P. Valdmanis, G.A. Rouleau, B.A. Hosler, P. Cortelli, P.J. de Jong, Y. Yoshinaga, J.L. Haines, M.A. Pericak-Vance, J. Yan, N. Ticozzi, T. Siddique, D. McKenna-Yasek, P.C. Sapp, H.R. Horvitz, J.E. Landers and R.H. Brown, Jr. (2009) Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. *Science*, **323**, 1205-8.
- 2 C. Vance, B. Rogelj, T. Hortobagyi, K.J. De Vos, A.L. Nishimura, J. Sreedharan, X. Hu, B. Smith, D. Ruddy, P. Wright, J. Ganesalingam, K.L. Williams, V. Tripathi, S. Al-Saraj, A. Al-Chalabi, P.N. Leigh, I.P. Blair, G. Nicholson, J. de Bellerocche, J.M. Gallo, C.C. Miller and C.E. Shaw (2009) Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. *Science*, **323**, 1208-11.
- 3 O. Broustal, A. Camuzat, L. Guillot-Noel, N. Guy, S. Millecamps, D. Deffond, L. Lacomblez, V. Golfier, D. Hannequin, F. Salachas, W. Camu, M. Didic, B. Dubois, V. Meininger, I. Le Ber and A. Brice (2010) FUS mutations in frontotemporal lobar degeneration with amyotrophic lateral sclerosis. *J Alzheimers Dis*, **22**, 765-9.
- 4 M.K. Andersson, A. Stahlberg, Y. Arvidsson, A. Olofsson, H. Semb, G. Stenman, O. Nilsson and P. Aman (2008) The multifunctional FUS, EWS and TAF15 proto-oncoproteins show cell type-specific expression patterns and involvement in cell spreading and stress response. *BMC Cell Biol*, **9**, 37.
- 5 I.R. Mackenzie, R. Rademakers and M. Neumann (2010) TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. *Lancet Neurol*, **9**, 995-1007.

- 6 C. Lagier-Tourenne, M. Polymenidou and D.W. Cleveland (2010) TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. *Hum Mol Genet*, **19**, R46-64.
- 7 I.R. Mackenzie, D.G. Munoz, H. Kusaka, O. Yokota, K. Ishihara, S. Roeber, H.A. Kretzschmar, N.J. Cairns and M. Neumann (2011) Distinct pathological subtypes of FTL-D-FUS. *Acta Neuropathol*, **121**, 207-18.
- 8 M. Neumann, D.M. Sampathu, L.K. Kwong, A.C. Truax, M.C. Micsenyi, T.T. Chou, J. Bruce, T. Schuck, M. Grossman, C.M. Clark, L.F. McCluskey, B.L. Miller, E. Masliah, I.R. Mackenzie, H. Feldman, W. Feiden, H.A. Kretzschmar, J.Q. Trojanowski and V.M. Lee (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. *Science*, **314**, 130-3.
- 9 H.X. Deng, H. Zhai, E.H. Bigio, J. Yan, F. Fecto, K. Ajroud, M. Mishra, S. Ajroud-Driss, S. Heller, R. Sufit, N. Siddique, E. Mugnaini and T. Siddique (2010) FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. *Ann Neurol*, **67**, 739-48.
- 10 M.J. Winton, L.M. Igaz, M.M. Wong, L.K. Kwong, J.Q. Trojanowski and V.M. Lee (2008) Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. *J Biol Chem*, **283**, 13302-9.
- 11 D. Dormann, R. Rodde, D. Edbauer, E. Bentmann, I. Fischer, A. Hruscha, M.E. Than, I.R. Mackenzie, A. Capell, B. Schmid, M. Neumann and C. Haass (2010) ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. *Embo J*, **29**, 2841-57.
- 12 M. Sendtner (2011) TDP-43: multiple targets, multiple disease mechanisms? *Nat Neurosci*, **14**, 403-5.

- 13 D. Dormann and C. Haass (2011) TDP-43 and FUS: a nuclear affair. *Trends Neurosci.*
- 14 G.S. Kaminski Schierle, C.W. Bertoncini, F.T. Chan, A.T. van der Goot, S. Schwedler, J. Skepper, S. Schlachter, T. van Ham, A. Esposito, J.R. Kumita, E.A. Nollen, C.M. Dobson and C.F. Kaminski (2011) A FRET sensor for non-invasive imaging of amyloid formation in vivo. *Chemphyschem*, **12**, 673-80.
- 15 V.V. Belzil, J. St-Onge, H. Daoud, A. Desjarlais, J.P. Bouchard, N. Dupre, W. Camu, P.A. Dion and G.A. Rouleau (2010) Identification of a FUS splicing mutation in a large family with amyotrophic lateral sclerosis. *J Hum Genet.*
- 16 M. DeJesus-Hernandez, J. Kocerha, N. Finch, R. Crook, M. Baker, P. Desaro, A. Johnston, N. Rutherford, A. Wojtas, K. Kennelly, Z.K. Wszolek, N. Graff-Radford, K. Boylan and R. Rademakers (2010) De novo truncating FUS gene mutation as a cause of sporadic amyotrophic lateral sclerosis. *Hum Mutat*, **31**, E1377-89.
- 17 M.C. Jud, M.J. Czerwinski, M.P. Wood, R.A. Young, C.M. Gallo, J.S. Bickel, E.L. Petty, J.M. Mason, B.A. Little, P.A. Padilla and J.A. Schisa (2008) Large P body-like RNPs form in *C. elegans* oocytes in response to arrested ovulation, heat shock, osmotic stress, and anoxia and are regulated by the major sperm protein pathway. *Dev Biol*, **318**, 38-51.
- 18 H. Ilieva, M. Polymenidou and D.W. Cleveland (2009) Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. *J Cell Biol*, **187**, 761-72.
- 19 D. Ito, M. Seki, Y. Tsunoda, H. Uchiyama and N. Suzuki (2011) Nuclear transport impairment of amyotrophic lateral sclerosis-linked mutations in FUS/TLS. *Ann Neurol*, **69**, 152-62.

- 20 Y. Kino, C. Washizu, E. Aquilanti, M. Okuno, M. Kurosawa, M. Yamada, H. Doi and N. Nukina (2010) Intracellular localization and splicing regulation of FUS/TLS are variably affected by amyotrophic lateral sclerosis-linked mutations. *Nucleic Acids Res.*
- 21 E. Yeh, T. Kawano, S. Ng, R. Fetter, W. Hung, Y. Wang and M. Zhen (2009) *Caenorhabditis elegans* innexins regulate active zone differentiation. *J Neurosci*, **29**, 5207-17.
- 22 S. Gao and M. Zhen (2011) Action potentials drive body wall muscle contractions in *Caenorhabditis elegans*. *Proc Natl Acad Sci U S A*, **108**, 2557-62.

Figure Legends

Figure 1

Transgene constructs. Wild-type full-length FUS (FL), FUS with 5 different clinical mutations (R514G, R521G, R522G, R524S, and P525L), and 2 truncated FUS (FUS513, and FUS501) were generated and injected into *C. elegans*. GFP, green fluorescent protein; QGSY-rich = Glutamine-Glycine-Serine-Tyrosine-rich region; G-Rich = Glycine-rich region; RRM = RNA recognition motif; RGG-rich = Arginine-Glycine-Glycine-rich region.

Figure 2

Representative images of transgenic FUS worms. (A) Live fluorescent images of neurons in the head and body, and (B) confocal microscopic images of immuno-stained animals. Non-transgenic N2 animals show no fluorescent signals with either wide-field (A) or confocal (B) microscope. GFP signals are observed almost exclusively in the nuclei in WT-FUS (WT), R514G and R521G (A, arrow). GFP signals in WT and R514G and DAPI perfectly overlap, suggesting that FUS in these 2 strains are exclusively expressed in the nucleus (B, WT, arrow). R522G animals show both nuclear (A and B, R522G, arrow) and cytoplasmic FUS (A and B, arrowhead), but nuclear signal is still stronger (A and B). P525L, FUS513 and FUS501 animals show marked cytoplasmic GFP signals (A and B, arrowheads), which are rather stronger than that in nuclei (A and B, arrows). Staining patterns with anti-GFP and anti-FUS antibodies are almost the same (B and supplementary Figure 2). There is no difference in distribution of GFP-positive neurons in each line. Scale bars; 20 μm (A) and 2.0 μm (B).

Figure 3

Features of transgenic worms. (A) Ratio of nuclear FUS in each transgenic strain. In WT-FUS animals (WT), $93 \pm 3\%$ of FUS is in the nucleus. Nuclear FUS in R514G and R521G do not differ from that in WT ($92 \pm 3\%$ and $96 \pm 3\%$, respectively). However, R522G and P525L show significantly lower ratio than WT ($59 \pm 10\%$ and $52 \pm 9\%$, respectively). FUS513 and FUS501 show even lower scores ($44 \pm 4\%$ and $43 \pm 5\%$ of WT, respectively) NS = not significant * = $p < 0.05$. *** = $p < 0.001$. (B and C) Immunoblot analyses of FUS aggregation: (B), Whole lysates (80 μ g) probed with anti-FUS or anti-GFP antibodies. α -Tubulin was used as a loading control. (C), RIPA soluble and RIPA insoluble/urea soluble fractions from the whole lysates were separated by sequential extraction, and probed with anti-FUS antibody. (D-F) Thrashing assays: (D) Motor activity as measured by the thrashing assay at 3 days of age. WT-FUS animals (WT) show slightly lower score than non-transgenic N2 animals ($p < 0.05$). Compared to WT, there is no decrease in R514G and R521G, but R522G and P525L animals show significantly lower score by $8.2 \pm 4.6\%$ and $12.5 \pm 5.0\%$, respectively ($p < 0.05$ for R521G, $p < 0.001$ for P525L). All truncated strains (FUS513 and FUS501) show marked decrease by approximately $33.5 \pm 8.5\%$ and $45.2 \pm 4.0\%$ of WT ($p < 0.001$). (E) Motor activity as measured by thrashing scores for 3-day-old and 6-day-old animals shows age-related reductions in motor activity in all strains ($11.9 \pm 3.7\%$ decrease in movement activity) in N2 non-transgenic animals. The extents of decline in movement activity in WT-FUS, R514G and R521G animals were not different from that of N2 animals. However, all of the other FUS mutants, including those associated with moderate and severe ALS phenotypes in humans (R522G, P525L, FUS513 and FUS501) show significantly larger decreases at 6 days of age ($p < 0.001$). NS = not significant; * = $p < 0.05$; *** = $p < 0.001$. (F) The rate of progression of motor impairment normalised to the activity at day 3 shows that the

R522L (moderate), R525L, FUS 513 and FUS501 (severe) animals have greater rates of progression in proportion to the severity of the human ALS phenotypes associated with those mutants.

Figure 4

Age-dependent changes of FUS-expressing *C. elegans*. (A), Representative microscopic images of transgenic FUS animals. At 3 days of age, all transgenic lines look similar in size, whereas at 6 days of age, P525L and FUS501 animals are slightly shrunk compared to WT-FUS animals. At 8 days of age, P525L and FUS501 animals are obviously smaller and pale. Scale bar; 0.2 mm for all images. (B), Kaplan-Meier survival curve and (C), lifespans. WT-FUS (WT), R514G, R521G animals live up to around 14 days, but most R522G, P525L, FUS513 and FUS501 animals died by 11 days (B). The life span of WT, R514G and R521G animals are not different for N2 animals, but those of R522G, P525L, FUS513 and FUS501 are significantly shorter than both N2 and WT-FUS animals (C). NS = not significant; *** = $p < 0.001$. (D) Fluorescent microscopic images of FUS aggregates in transgenic FUS animals. At 8 days of age (9 days for R522G), R522G, P525L, FUS513 and FUS501 animals show abundant FUS granules in the cytoplasm (arrows), which are not obvious in younger animals (3 days old). Scale bar: 2.0 μm .

Figure 5

Effects of heat shock on transgenic FUS animals. (A) PAB-1 expression, and (B) effect of heat shock. Under basal condition, PAB-1 is diffusely expressed in cytoplasm (A, no HS, arrow). Thirty minutes after heat shock, neurons developed some stress granules in cytoplasm

(A, 30 min, arrowheads), but most of them disappear 6 after heat shock (A, 6hr). Transgenic animals after single heat shock (B). There are more stress granules in WT-FUS (WT) animals after heat shock, but still FUS remains in the nucleolus (B, WT/HS(+), arrowheads). On the other hand, R522G, P525L and FUS501 animals show many granules that are both FUS and PAB-1 positive. (R522G/HS(+), P525L/HS(+), and FUS501/HS(+), open arrowheads). Scale bar: 2.0 μm . (C) Thrashing assay of transgenic animals with and without heat shock. WT-FUS (WT), R514G and R521G animals show no significant decrease after recovery from the heat shock, but all other strains (R522G, P525L, FUS513 and FUS501) show significantly decreased motor activity after heat shock. NS = not significant; *** = $p < 0.001$.

Figure 6

Localization of wild-type FUS in animals expressing mutant FUS. (A) Representative fluorescence microscopic images of TagRFP-WT-FUS;GFP-FUS P525L double transgenic animals with or without heat shock. The distribution of TagRFP-WT-FUS and GFP-FUS P525L proteins were not changed in double transgenic animals. After heat shock, GFP-FUS P525L protein formed numerous cytoplasmic granules (arrows), whereas TagRFP-WT-FUS remained in the nucleus. (B) Thrashing assay of the single and double transgenic animals. Co-expression of WT-FUS did not rescue motor activity impairment of double transgenic animal under basal conditions. After heat shock, WT-FUS animals recovered within 30 min, whereas both the single GFP-FUS P525L and double transgenic animals showed persistent motor impairment. NS = not significant; *** = $p < 0.001$.

Figure 1




Figure 2A




Figure 2B




Figure 3A




Figure 3B




Figure 3C




Figure 3D




Figure 3E




Figure 3F




Figure 4A




Figure 4B




Figure 4C




Figure 4D




Figure 5A




Figure 5B




Figure 5C




Figure 6A




Figure 6B

